Liquid Biopsy at the Frontier of Kidney Diseases: Application of Exosomes in Diagnostics and Therapeutics
Genes · 28.06.2023 · 14 (7) · 1367
DOI: 10.3390/genes14071367 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 28.06.2023. Verfasst von Ewud Agborbesong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Exosomes, Extracellular Vesicles, Kidney Diseases. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 253 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Institutes of Health T32.
Abstract (Originalsprache)
In the era of precision medicine, liquid biopsy techniques, especially the use of urine analysis, represent a paradigm shift in the identification of biomarkers, with considerable implications for clinical practice in the field of nephrology. In kidney diseases, the use of this non-invasive tool to identify specific and sensitive biomarkers other than plasma creatinine and the glomerular filtration rate is becoming crucial for the diagnosis and assessment of a patient’s condition. In recent years, studies have drawn attention to the importance of exosomes for diagnostic and therapeutic purposes in kidney diseases. Exosomes are nano-sized extracellular vesicles with a lipid bilayer structure, composed of a variety of biologically active substances. In the context of kidney diseases, studies have demonstrated that exosomes are valuable carriers of information and are delivery vectors, rendering them appealing candidates as biomarkers and drug delivery vehicles with beneficial therapeutic outcomes for kidney diseases. This review summarizes the applications of exosomes in kidney diseases, emphasizing the current biomarkers of renal diseases identified from urinary exosomes and the therapeutic applications of exosomes with reference to drug delivery and immunomodulation. Finally, we discuss the challenges encountered when using exosomes for therapeutic purposes and how these may affect its clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Pediatrics, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, TN 38105, USA.
- Children's Foundation Research Institute, Le Bonheur Children's Hospital, Memphis, TN 38105, USA.
- Pediatric Medicine Department, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- National Institutes of Health T32
Zitieren
APA
Agborbesong, E., Bissler, J., & Li, X. (2023). Liquid Biopsy at the Frontier of Kidney Diseases: Application of Exosomes in Diagnostics and Therapeutics. Genes, 14(7), 1367. https://doi.org/10.3390/genes14071367
Vancouver
Agborbesong E, Bissler J, Li X. Liquid Biopsy at the Frontier of Kidney Diseases: Application of Exosomes in Diagnostics and Therapeutics. Genes. 2023;14(7):1367. doi:10.3390/genes14071367
BibTeX
@article{Agborbesong2023,
author = {Agborbesong, Ewud and Bissler, John and Li, Xiaogang},
title = {Liquid Biopsy at the Frontier of Kidney Diseases: Application of Exosomes in Diagnostics and Therapeutics},
journal = {Genes},
year = {2023},
volume = {14},
number = {7},
pages = {1367},
doi = {10.3390/genes14071367}
}
EUVIMED